Tong Jie, Deng Chengyuan, Sun Guanghua, Zhou Jun, Zhong Peirui, Wang Tiantian, Zeng Ye, Wu Qi, Liao Yuan, Luo Fu, Peng Ting, Liao Ying
Department of Rehabilitation, The First Affiliated Hospital of University of South China, Hengyang 421001, Hunan, China.
Rehabilitation Laboratory, The First Affiliated Hospital of University of South China, Hengyang 421001, Hunan, China.
Evid Based Complement Alternat Med. 2021 Nov 1;2021:2047097. doi: 10.1155/2021/2047097. eCollection 2021.
Electroacupuncture (EA) has been clinically used in knee osteoarthritis broadly and proved to be effective than other therapies with fewer side effects; however, the mechanism of electroacupuncture to work on cartilage remains unclear. In this study, we aimed to evaluate the effect of EA treatment on cartilage and the relationship between EA and proteins such as HIF-a and SOX9. EA (dilatational wave, 3-15 HZ, 1 mA) has been applied to bilateral Zusanli (ST36), Xuehai (SP10), Taixi (KI3), and Yanglingquan (GB34) of rats. Results showed that the cartilage of the knee osteoarthritis group had obvious damage and fissure formation while the EA group showed that the cartilage destruction was generally milder. In addition, the protein expression levels of HIF-1, and chondrogenic markers such as Sox9, and ACAN in the electroacupuncture group were higher than those in the ACLT group. Also, the extracellular matrix protein expression levels of MMP13 and ADAMTS5 were decreased in the EA group. These findings indicate that EA could alleviate the severity of knee osteoarthritis, and HIF-a and SOX9 may closely attribute to the treatment.
电针(EA)已在膝关节骨关节炎的临床治疗中广泛应用,且被证明比其他疗法更有效,副作用更少;然而,电针对软骨起作用的机制仍不清楚。在本研究中,我们旨在评估电针治疗对软骨的影响以及电针与缺氧诱导因子-α(HIF-α)和SRY-盒转录因子9(SOX9)等蛋白质之间的关系。将电针(疏密波,3 - 15赫兹,1毫安)施加于大鼠双侧足三里(ST36)、血海(SP10)、太溪(KI3)和阳陵泉(GB34)。结果显示,膝关节骨关节炎组的软骨有明显损伤和裂隙形成,而电针组显示软骨破坏总体较轻。此外,电针组中缺氧诱导因子-1(HIF-1)以及软骨生成标志物如SRY-盒转录因子9(Sox9)和聚集蛋白聚糖(ACAN)的蛋白表达水平高于前交叉韧带切断术(ACLT)组。而且,电针组中基质金属蛋白酶13(MMP13)和含血小板反应蛋白基序的解聚蛋白样金属蛋白酶5(ADAMTS5)的细胞外基质蛋白表达水平降低。这些发现表明,电针可减轻膝关节骨关节炎的严重程度,且缺氧诱导因子-α(HIF-α)和SRY-盒转录因子9(SOX9)可能与该治疗密切相关。